FDA has standardized bioequivalence administration protocols across product-specific guidances for generic chewable tablets, aligning administration procedures with harmonized international testing standards. The regulatory update is aimed at improving consistency in how BE trials administer and assess chewable solid dose forms. The change targets a practical bottleneck in generic development: variability in administration conditions can complicate cross-comparability of BE study results. Standardization reduces ambiguity for sponsors and may support more predictable review timelines. For formulators and CMC teams, the updated protocols may influence trial design details such as dosing instructions and administration timing within crossover studies. While not a therapeutic approval, the decision affects downstream market access and can shape how quickly generic manufacturers can enter or expand portfolios in chewable segments.